BRIDGEBIO PHARMA INC. - COMMON STOCK

BridgeBio Pharma Receives FDA Fast Track Designation for Investigational Gene Therapy for Congenital Adrenal Hyperplasia

14 May 2021 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. Reports First Quarter 2021 Financial Results And Business Update

06 May 2021 06:30:01 By Nasdaq GlobeNewswire

BridgeBio Pharma and the University of California, San Diego Announce Collaboration to Advance Treatments for Genetically Driven Conditions

13 Apr 2021 06:45:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and UC Davis Establish Collaboration to Transform Research into Potential Therapies for Genetically Driven Diseases

13 Apr 2021 06:42:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and Roswell Park Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Cancers

13 Apr 2021 06:40:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and Oregon Health & Science University Establish Collaboration to Translate Pioneering Research into Therapies for Genetically Driven Diseases

13 Apr 2021 06:37:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and The Lundquist Institute Collaborate to Advance Treatments for Genetically Driven Conditions and Cancers

13 Apr 2021 06:35:00 By Nasdaq GlobeNewswire

BridgeBio Pharma, Inc. and GlycoNet Initiate Collaboration to Discover Potential Treatments for Genetic Diseases through Glycomics Research

13 Apr 2021 06:32:00 By Nasdaq GlobeNewswire

BridgeBio Pharma and Brown University Announce Partnership to Drive the Advancement of Academic Innovations in Genetically Driven Diseases into Potential Therapeutics for Patients

13 Apr 2021 06:30:00 By Nasdaq GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Apr 2021 15:30:00 By Nasdaq GlobeNewswire